Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz–Jeghers syndrome patients

Rodney J. Scott(New South Wales Department of Health), AD Spigelman(University of Newcastle Australia), L. Thomas(University of Liverpool), CJA Smith(University of Newcastle Australia), Renee Crooks(John Hunter Hospital), Cliff Meldrum(New South Wales Department of Health), Mary McPhillips(John Hunter Hospital), David Mowat(UNSW Sydney)
Clinical Genetics
October 1, 2002
10.1034/j.1399-0004.2002.620405.x
Cited by 66

Related Papers

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
|Pediatric Neurology|2013|1.5k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k